Metabolic Differences Between Subtypes of Polycystic Ovary Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-01

Study Completion Date

2023-07-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We aimed to investigate serum uric acid levels in patients with different phenotype of policystic ovary syndrome and to compare healthy controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Visceral Adiposity Index Differences Between Subtypes of Polycystic Ovary Syndrome

NCT06358300

Visceral Adiposity Index Polycystic Ovary Syndrome

COMPLETED

Evaluation of Serum Scube-1 Scube-2 and Scube-3 Levels in Patients With Polikistik Over Syndrome ,

NCT03765905

Polycystic Ovary Syndrome

COMPLETED

Congenital Uterine Anomalies & Pregnancy in Polycystic Ovarian Syndrome

NCT04776915

Mullerian Anomaly of Uterus, Nec

UNKNOWN

History of Polycystic Ovary Syndrome in First-degree Relatives

NCT06442228

Polycystic Ovary Syndrome

COMPLETED NA

Advanced Glycation End Products and Dietary Intervention in Polycystic Ovary Patients

NCT05830487

Polycystic Ovary Syndrome Diet Habit

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The final breakdown product of adenosine and guanosine-based purines formed as a result of the breakdown of nucleic acids is uric acid (UA). Uric acid has many beneficial and harmful properties for humans. One of the most important benefits of uric acid is that it can act as an antioxidant and is perhaps one of the most important antioxidants in plasma. However, this hypothesis is completely opposite to the hypothesis advocating an increase in the incidence of hyperuricemia and cardiovascular events. There are also experimental studies showing that UA, which has an antioxidant effect in the extracellular fluid, has harmful effects when it enters the cell. Uric acid can contribute to molecular endothelial dysfunction, oxidative stress and the formation of many oxygen radicals, disruption of the vasodilation mechanism, and increased inflammation. A correlation has been found between insulin resistance and serum UA level in patients with metabolic syndrome. It has been reported in some studies that hyperuricemia can be considered as an indicator of insulin resistance in these patients. At the same time, many studies have reported that both insulin resistance and hyperuricemia increase cardiovascular risk. In a study, it was stated that every 1 mg/dL increase in serum UA level in women increased the risk of ischemic heart disease by 12%.

Polycystic ovary syndrome (PCOS) is one of the endocrinological diseases that affects 5-20% of women of reproductive age. It is characterized by oligoanovulation, clinical or biochemical hyperandrogenemia and the appearance of polycystic ovaries. This syndrome is diagnosed according to the revised 2003 Rotterdan criteria; These criteria; 1) Oligo-anovulation, 2) Clinical and/or biochemical hyperandrogenism findings, 3) Polycystic ovary (PCO) appearance in the ovaries. For diagnosis, it is sufficient to have two of these criteria and not have another disease that causes this.

Polycystic ovary syndrome; Metabolic disorders such as insulin resistance, dyslipidemia, glucose intolerance, hypertension and obesity are often accompanied, and increased inflammation is one of the main characteristics of this syndrome. While the presence or absence of PCOS was important until recently, recent studies have shown that metabolic changes and inflammation occur at different degrees in different subtypes of PCOS. Therefore, PCOS cases are divided into 4 subtypes. These; Subtype 1 has hyperandrogenemia + oligoanovulation + PCO appearance on ultrasonography (USG), Subtype 2 has hyperandrogenemia + oligoanovulation, Subtype 3 has hyperandrogenemia + PCO appearance on USG, and Subtype 4 has oligoanovulation + PCO appearance on USG. As the subtype number of polycystic ovary syndrome decreases, the severity and frequency of metabolic disorders and inflammation accompanying polycystic ovary syndrome increase.

Hyperuricemia is one of the common metabolic disorders in patients with PCOS. Prevalence studies have shown that the frequency of hyperuricemia in patients with PCOS is approximately 25%, 3 times higher than in controls. However, these studies were conducted in the general PCOS patient group, and patients with different subtypes were not evaluated.

Since there are different metabolic effects in different subtypes of polycystic ovary syndrome; In this study we aimed to investigate whether there is a difference between serum UA levels in different PCOS subtypes. Studies investigating UA levels in subtypes of PCOS are rare in the literature. We aim to contribute to the knowledge in this field with the results we obtained from this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uric Acid Concentration, Serum, Quantitative Trait Locus 7 Polycystic Ovary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.